| Name | Fanotaprim |
| Description | Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM, a hDHFR IC50 of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196. |
| In vitro | Fanotaprim exhibits parasiticidal and antiproliferative effects with EC50s of 13 and 7300 nM against the type I RH strain of T. gondii and MCF-7 cells, respectively[1]. It also inhibits the growth of T. gondii strains in vitro with EC50s ranging from 7.6 to 29.8 nM (GT1, ME49, CTG, RUB, and VAND)[1]. |
| In vivo | Fanotaprim (1-10 mg/kg; p.o.; daily; beginning on day 1 through day 7) is highly effective in controlling acute infection by highly virulent strains of T. gondii in the murine model[1]. In mice, Fanotaprim (1 mg/kg; i.v.) shows CL, Vd, and t1/2 values of 10.6 mL/min/kg, 1.14 L/kg, and 3.9 hours, respectively[1]. When administered orally at 0.83 mg/kg, Fanotaprim exhibits F, Cmax, Tmax, and AUC0-last values of 47.3%, 178 ng/mL, 0.05 hours, and 750 ng h/mL, respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (66.06 mM)
|
| Keywords | CD-1 | Inhibitor | Fanotaprim | mice | VYR 006 | DHFR | VYR-006 | inhibit | Antifolate | dhydrofolate | reductase | survival | toxoplasmosis | VYR006 |
| Inhibitors Related | Pemetrexed | Urea | Trimethoprim | Pyrimethamine | Piritrexim | Diaveridine | Pemetrexed disodium hemipenta hydrate | Gentamicin sulfate | Pemetrexed disodium | LY 345899 | Methotrexate Diglutamate | Sulfameter |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Anti-Parasitic Compound Library | Bioactive Compound Library | Inhibitor Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
